Yesterday, the CMO of Invitae (NVTA), Robert Nussbaum, sold shares of NVTA for $517.1K.
Following Robert Nussbaum’s last NVTA Sell transaction on May 22, 2019, the stock climbed by 8.4%. In addition to Robert Nussbaum, 5 other NVTA executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Invitae’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $53.48 million and GAAP net loss of $48.68 million. In comparison, last year the company earned revenue of $37.31 million and had a GAAP net loss of $31.67 million. The company has a one-year high of $28.75 and a one-year low of $9.04.
Robert Nussbaum’s trades have generated a -67.1% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.
